Inflammation and Incretins
Amitabh Hatwal
Indian Journal of Endocrinology and Metabolism · 2012
doi:10.4103/2230-8210.104049 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique role in modulating this inflammatory process. Incretin based therapies have shown beneficial anti-inflammatory effects on surrogate markers but cardiovascular outcome data is still lacking.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.